Last Updated : Oct 26, 2020 10:57 AM IST | Source: PTI

Third phase human trial of COVID-19 vaccine to commence in Bhubaneswar soon

The search for a suitable vaccine for COVID-19 has almost come to the final stage, Dr E Venkata Rao, Principal Investigator in the COVAXIN human trial and Professor in the department of Community Medicine at the Institute of Medical Sciences and SUM Hospital here said on Sunday.

PTI

The third phase of the human trial of the indigenous vaccine against COVID-19, COVAXIN, will commence at a private hospital here soon, an official said.

The search for a suitable vaccine for COVID-19 has almost come to the final stage, Dr E Venkata Rao, Principal Investigator in the COVAXIN human trial and Professor in the department of Community Medicine at the Institute of Medical Sciences and SUM Hospital here said on Sunday.

IMS and SUM Hospital is among the 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted.

The indigenous vaccine, being developed by ICMR and Bharat Biotech has received the approval of the Central Drugs Standard Control Organisation (CDSCO) for initiating the third phase trial. After completion of the first and second phase of the trial with demonstrable safety profile and immunogenicity, the large-scale efficacy trial involving thousands of volunteers has been planned now, Dr Rao said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

related news

Dr Rao, who is the head of the Preventive and Therapeutic Clinical Trial Unit (PTCTU), said during this phase the age limit and eligibility/ screening criteria would be relaxed and several volunteers who are otherwise apparently healthy would be recruited for the trial.

Like the previous phases, half of the volunteers would receive placebo and the remaining half would be administered COVAXIN in this phase. Even health care workers would be recruited for the trial. The volunteers would be followed up over a considerable period of time to look at the efficacy of the vaccine in preventing the development of the Corona disease, he said.

Rao said there had been a huge response and enthusiasm among people who had offered themselves to be volunteers for the trial. He said persons above 18 years will be taken for the human trial.

The interested volunteers for the project could enrol themselves for the trial by registering online at www.ptctu.soa.ac under the section register for clinical trials, he said.
First Published on Oct 26, 2020 10:58 am